SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-19-000203
Filing Date
2019-03-12
Accepted
2019-03-12 17:19:56
Documents
2
Group Members
ORBIMED CAPITAL GP V LLCORBIMED CAPITAL LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 11 ss129003_sc13da.htm SC 13D/A 158279
2 JOINT FILING AGREEMENT ss129003_ex9901.htm EX-99.1 16925
  Complete submission text file 0000947871-19-000203.txt   176732
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Subject) CIK: 0001612042 (see all company filings)

IRS No.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88586 | Film No.: 19675976
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences